Abstract
More than 500 000 new patients each year worldwide contract head and neck cancers.1 During the past 30 years, the 3- to 5-year survival rate of patients with advanced T3 and T4 squamous cell carcinoma (SCC) of the head and neck (HNSCC) has remained poor (20%-30%) despite considerable advances in surgical techniques and irradiation delivery and improvement in chemotherapeutic strategies. Given these dismal figures, advances in gene therapy give new hope for primary or adjuvant treatment of HNSCC. Patients with HNSCC have been well documented to exhibit local immunosuppression with depressed T-cell–meditated responses as well as depressed natural killer (NK) cell and antibody-dependent cell cytotoxic effects.2

This publication has 10 references indexed in Scilit: